drugset / Trial / NCT03970993

VAC 072-An Efficacy Study of R21/MM in Different Dose Schedules

NCT03970993

Phase 1/2 Completed 78 enrolled University of Oxford
Non-randomizedParallel-groupOpen-labelPrevention

Summary

An open label, partially blinded clinical trial in which healthy volunteers will be administered experimental malaria vaccines. There will be seven experimental groups of volunteers, of which five receive vaccination with the novel malaria vaccine candidate, R21, in combination with the vaccine adjuvant, Matrix M. The study will assess the safety \& immune responses to vaccination, and the efficacy of the vaccine.

Timeline

Start
2019-06-17
Primary completion
2021-08-24
Completion
2021-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject R21 Vaccine 2 ug Intramuscular
Subject R21 Vaccine 10 ug Intramuscular
Subject R21 Vaccine 50 ug Intramuscular
Background Matrix-M1 Adjuvant Other / unclassified 50 ug Intramuscular

Indications